1. The skin vasoconstrictor assay does not correlate significantly to airway or systemic responsiveness to inhaled budesonide in asthmatic patients

   • Andrew M. Wilson
   • Wendy J. R. Coutie
   • Brian J. Lipworth

   Pharmacodynamics 30 January 2003 Pages: 643 - 647

   

2. Intrarectal pharmacokinetics of two formulations of quinine in children with falciparum malaria

   • H. Barennes
   • H. Sterlingot
   • E. Pussard

   Pharmacokinetics and Disposition 29 January 2003 Pages: 649 - 652

   

3. Effect of ciprofloxacin on the pharmacokinetics of ropivacaine

   • Mika J. Jokinen
   • Klaus T. Olkkola
   • Pertti J. Neuvonen

   Pharmacokinetics and Disposition 29 January 2003 Pages: 653 - 657

   

4. CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects

   • Koichi Ohara
   • Shigeru Tanabu
   • Haruo Shibuya

   Pharmacokinetics and Disposition Pages: 659 - 661

5. Identification of epoxybergamottin as a CYP3A4 inhibitor in grapefruit peel

   • H. Wangensteen
   • E. Molden
   • K. E. Malterud

   Pharmacokinetics and Disposition 30 January 2003 Pages: 663 - 668

   

6. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment

   • S. G. Simonson
   • P. D. Martin
   • M. J. Warwick

   Pharmacokinetics and Disposition 30 January 2003 Pages: 669 - 675

   

7. Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo

   • Päivi K. Myllynen
   • Päivi K. Pienimäki
   • Kirsi H. Vähäkangas

   Pharmacokinetics and Disposition 30 January 2003 Pages: 677 - 682

   

8. A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate

   • Milan Zdravkovic
   • Anette K. Olsen
   • Mapoko M. Ilondo

   Pharmacokinetics and Disposition 06 February 2003 Pages: 683 - 688

   

9. Initial 3-month usage characteristics predict long-term use of benzodiazepines: an 8-year follow-up

   • Rolf van Hulten
   • K. Bart Teeuw
   • Hubert G. Leufkens

   Pharmacoepidemiology and Prescription 07 February 2003 Pages: 689 - 694

10. Use of calcium antagonists and worsening renal function in patients receiving angiotensin-converting-enzyme inhibitors

    • Giuseppe Zuccalà
    • Graziano Onder
    • Roberto Bernabei

    Pharmacoepidemiology and Prescription 31 January 2003 Pages: 695 - 699

11. Determinants for drug prescribing to children below the minimum licensed age

    • Geert W. 't Jong
    • Ingo A. Eland
    • Bruno H. C. Stricker

    Pharmacoepidemiology and Prescription 06 February 2003 Pages: 701 - 705

12. Reporting adverse drug reactions on a geriatric ward: a pilot project

    • Annemie Somers
    • Mirko Petrovic
    • Marc Bogaert

    Pharmacoepidemiology and Prescription Pages: 707 - 714

13. Low plasma cefaclor levels in cystectomized bladder cancer patients with various types of urinary diversion

    • F. Mattioli
    • P. Tognoni
    • A. Martelli

    Letter to the Editor Pages: 715 - 716

14. Raynaud's phenomenon induced by drugs acting on neurotransmission: two cases under reboxetine and one under tegaserod

    • Raffaela Bertoli
    • François Girardin
    • Bernhard H. Lauterburg

    Letter to the Editors 29 January 2003 Pages: 717 - 717